2 minute read
Cancer Resources and Clinical Trials
Cancer Resources
DrConnect® (for physicians)
Our practice-tested DrConnect® service elevates the team approach to a new level by giving you and your staff an instantaneous, comprehensive and secure online view of your patients’ treatment progress while at Cleveland Clinic. With DrConnect®, our specialty care becomes a seamless part of your practice, providing you with added confidence when making decisions regarding the next step in your patients’ care.
To get more information or to sign up online, please visit clevelandclinic.org/drconnect or call our DrConnect® help desk at 877.224.7367.
Request for Medical Records
To request medical records, please contact Health Information Management at 954.659.5000.
Patient Appointment Center
To schedule an appointment with one of our specialists, patients may call 877.463.2010.
Follow us on Twitter @Cancer_CCFla
Support and Counseling Services
To speak with one of our Maroone Cancer Center staff and to schedule an appointment for support services, call
954.659.5840.
• Art Therapy Services • Caring Touch Services
• Dietary Services and
Nutritional Counseling • Genetic Counseling • Music Therapy Services • Patient Navigation Services • Psychological Services
- Beauty/Body
Image Services - Chair Yoga - Reiki - Craniosacral
Therapy - Gentle Yoga - Reflexology - Gentle
Therapeutic
Massages
• Social Work Services • Support Groups • Survivorship Services • Wig Boutique and
Wellness Store
Additional information is available in our Patient Resource and Education Center located on the 1st floor of the Egil and Pauline Braathen Center or online at ClevelandClinicFlorida.org/
SupportServices.
Clinical Trials
Maroone Cancer Center is participating in a clinical trial to evaluate the impact of the DecisionDx®-Melanoma gene expression profile on sentinel lymph node biopsy decisions and clinical outcomes.
Until recently, physicians have relied on traditional clinical and pathological factors to determine whether melanoma is likely to spread to the lymph nodes and elsewhere in the body. DecisionDx-Melanoma analyzes the genetic profile of an individual patient’s melanoma tissue to gauge the risk of metastasis or recurrence more accurately and determine the need for an invasive sentinel lymph node biopsy. Patients with a positive sentinel lymph node biopsy are at higher risk for recurrence and are considered eligible for immunotherapy to decrease the risk of melanoma recurrence.
“It’s difficult to predict whether early-stage melanoma will spread to the lymph nodes,” explains Maroone Cancer Center oncologist Timmy Nguyen, MD. “You can’t do a biopsy for everyone because the majority of cases will not have melanoma involved in the lymph nodes, and those procedures can cause complications. So, this test is used along with the tissue specimen viewed under a microscope to be a better and more personalized predictor of risk.”
The test results also may guide the intensity of follow-up surveillance after initial surgical removal of the melanoma, Dr. Nguyen adds.
The trial will evaluate the association between use of DecisionDx-Melanoma and sentinel lymph node biopsy decisions, and will track five-year clinical outcomes of patients who undergo the genetic testing. Study participants must be at least 18 years old with newly diagnosed invasive melanoma being considered for sentinel lymph node biopsy.
Anyone interested in participating in the trial should contact Sharon Lew, MHA, CCRP, Cancer Clinical Research Program Supervisor at Maroone Cancer Center, at lews2@ccf. org. For more information, visit ClevelandClinicFlorida.org/
